GlassScriptPhysician profile
Krishna Patel
NPI 1144035619
$1,308.14
in general payments reported to CMS, 2019-2025
12 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $216.48 | 2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $192.02 | 2025 | Dupixent |
| Csl Behring | $189.94 | 2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $175.33 | 2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $171.57 | 2025 | |
| Optinose US, INC. | $126.08 | 2025 | |
| Genentech USA, INC. | $57.18 | 2025 | Xolair |
| Grifols USA, LLC | $55.42 | 2025 | Xembify |
| Genzyme Corporation | $48.28 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $25.77 | 2025 | Neffy |
| Incyte Corporation | $25.57 | 2025 | Opzelura |
| Octapharma USA, INC. | $24.50 | 2025 | Cutaquig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.